• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Galcanezumab-induced fixed drug eruption.

作者信息

Klager Skylar, Khalil Marina, Shulman Kenneth, Sami Naveed

机构信息

University of Central Florida College of Medicine, Orlando, Florida.

UCF Health, Orlando, Florida.

出版信息

JAAD Case Rep. 2021 Jan 30;9:90-92. doi: 10.1016/j.jdcr.2021.01.015. eCollection 2021 Mar.

DOI:10.1016/j.jdcr.2021.01.015
PMID:33665287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7907008/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42d2/7907008/a5508dd69962/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42d2/7907008/4c2991feabc0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42d2/7907008/a5508dd69962/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42d2/7907008/4c2991feabc0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42d2/7907008/a5508dd69962/gr2.jpg

相似文献

1
Galcanezumab-induced fixed drug eruption.加卡奈珠单抗诱发的固定性药疹。
JAAD Case Rep. 2021 Jan 30;9:90-92. doi: 10.1016/j.jdcr.2021.01.015. eCollection 2021 Mar.
2
Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization.固定性药疹成功脱敏：固定性药疹皮损表皮中CD25+CD4+ T细胞的存在可能参与脱敏诱导过程。
Dermatology. 2004;209(1):29-32. doi: 10.1159/000078583.
3
Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy.每月一次注射加卡尼单抗预防成人偏头痛：基于证据的描述性综述及在治疗中的潜在地位
Ther Clin Risk Manag. 2019 Apr 11;15:557-569. doi: 10.2147/TCRM.S159690. eCollection 2019.
4
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.降钙素基因相关肽（CGRP）拮抗剂治疗的历史和综述：从转化研究到治疗。
Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22.
5
Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.抗降钙素基因相关肽（CGRP）治疗药物：美国头痛学会第 60 届科学会议（2018 年 6 月，旧金山）后对既往综述的更新。
Headache. 2018 Nov;58 Suppl 3:276-290. doi: 10.1111/head.13417.
6
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.CGRP结合单克隆抗体LY2951742（加卡尼单抗）在健康志愿者中的安全性、耐受性、药代动力学和药效学
Front Pharmacol. 2017 Oct 17;8:740. doi: 10.3389/fphar.2017.00740. eCollection 2017.
7
Reducing Episodic Cluster Headaches: Focus on Galcanezumab.减轻发作性丛集性头痛：聚焦于加卡奈珠单抗。
J Pain Res. 2020 Jul 2;13:1591-1599. doi: 10.2147/JPR.S222604. eCollection 2020.
8
Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.健康受试者和偏头痛患者皮下给予降钙素基因相关肽（CGRP）抗体格尔卡奈珠单抗后的群体药代动力学。
J Clin Pharmacol. 2020 Feb;60(2):229-239. doi: 10.1002/jcph.1511. Epub 2019 Sep 4.
9
Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.降钙素基因相关肽（CGRP）拮抗剂及其在偏头痛治疗中的应用。
J Pain Palliat Care Pharmacother. 2020 Mar;34(1):22-31. doi: 10.1080/15360288.2019.1690616. Epub 2019 Nov 25.
10
Galcanezumab: First Global Approval.加巴喷丁：全球首次批准。
Drugs. 2018 Nov;78(16):1769-1775. doi: 10.1007/s40265-018-1002-7.

引用本文的文献

1
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data.降钙素基因相关肽单克隆抗体治疗偏头痛预防：真实世界数据的系统评价。
Cells. 2022 Dec 29;12(1):143. doi: 10.3390/cells12010143.

本文引用的文献

1
Fixed Drug Eruption to Biologics and Role of Lesional Patch Testing.生物制剂所致固定性药疹及皮损斑贴试验的作用
J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2398-2399. doi: 10.1016/j.jaip.2019.06.028. Epub 2019 Jul 17.
2
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.加巴喷丁在慢性偏头痛中的应用：一项随机、双盲、安慰剂对照的 REGAIN 研究。
Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.
3
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
一项评估加尼卡珠单抗治疗偏头痛患者的 3 期、长期、开放性标签安全性研究。
BMC Neurol. 2018 Nov 9;18(1):188. doi: 10.1186/s12883-018-1193-2.
4
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.加巴喷丁在预防阵发性偏头痛中的疗效和安全性：EVOLVE-2 期 3 随机对照临床试验结果。
Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31.
5
Immunogenicity of protein therapeutics: The key causes, consequences and challenges.蛋白质治疗药物的免疫原性：关键原因、后果及挑战。
Self Nonself. 2010 Oct;1(4):314-322. doi: 10.4161/self.1.4.13904.
6
Fixed drug eruption induced by an iodinated non-ionic X-ray contrast medium: a practical approach to identify the causative agent and to prevent its recurrence.碘化非离子型X线造影剂诱发的固定性药疹：识别致病因素及预防复发的实用方法
Eur Radiol. 2007 Feb;17(2):485-9. doi: 10.1007/s00330-006-0371-6. Epub 2006 Aug 26.
7
Fixed drug eruption with interferon-beta-1b.注射用干扰素β-1b引发的固定性药疹。
Australas J Dermatol. 2005 Aug;46(3):154-7. doi: 10.1111/j.1440-0960.2005.00168.x.
8
Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption.在固定性药疹免疫病理效应部位的效应记忆型表皮内T细胞产生γ干扰素的直接证据。
Am J Pathol. 2002 Oct;161(4):1337-47. doi: 10.1016/s0002-9440(10)64410-0.
9
Fixed drug eruptions. Incidence, recognition, and avoidance.固定性药疹。发病率、识别与避免
Am J Clin Dermatol. 2000 Sep-Oct;1(5):277-85. doi: 10.2165/00128071-200001050-00003.
10
Fixed drug eruption caused by lactose in an injected botulinum toxin preparation.注射用肉毒毒素制剂中乳糖引起的固定型药疹。
J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):263-4. doi: 10.1016/s0190-9622(99)70202-1.